274 related articles for article (PubMed ID: 20381114)
1. DNA methyltransferases 1, 3a, and 3b overexpression and clinical significance in gastroenteropancreatic neuroendocrine tumors.
Rahman MM; Qian ZR; Wang EL; Yoshimoto K; Nakasono M; Sultana R; Yoshida T; Hayashi T; Haba R; Ishida M; Okabe H; Sano T
Hum Pathol; 2010 Aug; 41(8):1069-78. PubMed ID: 20381114
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of DNA methyltransferases 1, 3a, and 3b significantly correlates with retinoblastoma tumorigenesis.
Qu Y; Mu G; Wu Y; Dai X; Zhou F; Xu X; Wang Y; Wei F
Am J Clin Pathol; 2010 Nov; 134(5):826-34. PubMed ID: 20959668
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic significance of DNA methyltransferase 1, 3a, and 3b overexpression in Tunisian breast cancers.
Ben Gacem R; Hachana M; Ziadi S; Ben Abdelkarim S; Hidar S; Trimeche M
Hum Pathol; 2012 Oct; 43(10):1731-8. PubMed ID: 22520950
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase-2 expression in gastroenteropancreatic neuroendocrine tumors.
Ince AT; Ovünç O; Celikel CA; Göksel S; Tosun S; Peker O
Hepatogastroenterology; 2007 Jun; 54(76):1125-9. PubMed ID: 17629053
[TBL] [Abstract][Full Text] [Related]
5. Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas.
Girault I; Tozlu S; Lidereau R; Bièche I
Clin Cancer Res; 2003 Oct; 9(12):4415-22. PubMed ID: 14555514
[TBL] [Abstract][Full Text] [Related]
6. Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors.
Shida T; Kishimoto T; Furuya M; Nikaido T; Koda K; Takano S; Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Tanizawa T; Nakatani Y; Miyazaki M
Cancer Chemother Pharmacol; 2010 Apr; 65(5):889-93. PubMed ID: 19657638
[TBL] [Abstract][Full Text] [Related]
7. DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas.
Peng DF; Kanai Y; Sawada M; Ushijima S; Hiraoka N; Kitazawa S; Hirohashi S
Carcinogenesis; 2006 Jun; 27(6):1160-8. PubMed ID: 16537562
[TBL] [Abstract][Full Text] [Related]
8. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
[TBL] [Abstract][Full Text] [Related]
9. [Genetic profile of gastroenteropancreatic neuroendocrine tumors].
Cabezas Agrícola JM
Endocrinol Nutr; 2009 Apr; 56 Suppl 2():16-9. PubMed ID: 19627765
[TBL] [Abstract][Full Text] [Related]
10. Tumor suppressor genes in the 9p21 gene cluster are selective targets of inactivation in neuroendocrine gastroenteropancreatic tumors.
Lubomierski N; Kersting M; Bert T; Muench K; Wulbrand U; Schuermann M; Bartsch D; Simon B
Cancer Res; 2001 Aug; 61(15):5905-10. PubMed ID: 11479232
[TBL] [Abstract][Full Text] [Related]
11. Loss of nuclear p27 expression and its prognostic role in relation to cyclin E and p53 mutation in gastroenteropancreatic neuroendocrine tumors.
Grabowski P; Schrader J; Wagner J; Hörsch D; Arnold R; Arnold CN; Georgieva I; Stein H; Zeitz M; Daniel PT; Sturm I
Clin Cancer Res; 2008 Nov; 14(22):7378-84. PubMed ID: 19010853
[TBL] [Abstract][Full Text] [Related]
12. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease.
Grabowski P; Griss S; Arnold CN; Hörsch D; Göke R; Arnold R; Heine B; Stein H; Zeitz M; Scherübl H
Neuroendocrinology; 2005; 81(1):1-9. PubMed ID: 15809513
[TBL] [Abstract][Full Text] [Related]
13. Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers.
Xiong Y; Dowdy SC; Xue A; Shujuan J; Eberhardt NL; Podratz KC; Jiang SW
Gynecol Oncol; 2005 Mar; 96(3):601-9. PubMed ID: 15721400
[TBL] [Abstract][Full Text] [Related]
14. Expression pattern and clinical significance of DNA methyltransferase 3B variants in gastric carcinoma.
Su X; Lv C; Qiao F; Qiu X; Huang W; Wu Q; Zhao Z; Fan H
Oncol Rep; 2010 Mar; 23(3):819-26. PubMed ID: 20127025
[TBL] [Abstract][Full Text] [Related]
15. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
[TBL] [Abstract][Full Text] [Related]
16. TNF-alpha promoter single nucleotide polymorphisms in gastroenteropancreatic neuroendocrine tumors.
Berković M; Cacev T; Zjacić-Rotkvić V; Kapitanović S
Neuroendocrinology; 2006; 84(5):346-52. PubMed ID: 17164537
[TBL] [Abstract][Full Text] [Related]
17. NFKB1 -94 insertion/deletion ATTG polymorphism in gastroenteropancreatic neuroendocrine tumors.
Burnik FS; Yalçin S
Chemotherapy; 2009; 55(5):381-5. PubMed ID: 19752553
[TBL] [Abstract][Full Text] [Related]
18. Increased DNA methyltransferase 1 (DNMT1) protein expression in precancerous conditions and ductal carcinomas of the pancreas.
Peng DF; Kanai Y; Sawada M; Ushijima S; Hiraoka N; Kosuge T; Hirohashi S
Cancer Sci; 2005 Jul; 96(7):403-8. PubMed ID: 16053511
[TBL] [Abstract][Full Text] [Related]
19. Telomere length abnormalities and telomerase RNA component expression in gastroenteropancreatic neuroendocrine tumors.
Kim HS; Lee HS; Nam KH; Choi J; Kim WH
Anticancer Res; 2015 Jun; 35(6):3501-10. PubMed ID: 26026117
[TBL] [Abstract][Full Text] [Related]
20. A Subset of Large Cell Neuroendocrine Carcinomas in the Gastroenteropancreatic Tract May Evolve from Pre-existing Well-Differentiated Neuroendocrine Tumors.
Pelosi G; Bianchi F; Dama E; Metovic J; Barella M; Sonzogni A; Albini A; Papotti M; Gong Y; Vijayvergia N
Endocr Pathol; 2021 Sep; 32(3):396-407. PubMed ID: 33433886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]